clinical trial · NCT06467201
SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females
Healthy Postmenopausal WomenKSHN001126 150mgKSHN001126 300mgKSHN001126 600mg
brief summary
This is an Open-label, Sequential dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of KSHN001126 in Healthy Human Post-Menopausal Female Volunteers. The primary objective of the study is to evaluate the safety and tolerability of increasing single doses of KSHN001126 while the secondary objective is to evaluate the plasma PK profile of KSHN001126 and its metabolites (KSHN001167, KSHN001168 and Fulvestrant) following ascending single oral doses of KSHN001126.
started
Jun 3, 2024
primary completion
Dec 8, 2024
completion
Mar 12, 2025
last updated
Feb 19, 2026
official title
An Open-label, Sequential Dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Human Post-Menopausal Female Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol